Ashurst advises Jefferies International as sponsor in relation to a disposal by PureTech Health plc

PureTech is a clinical stage biotechnology company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases. PureTech had previously disposed of Karuna common stock which, when aggregated over the last 12 months, had the result that any further material disposals would constitute a class 1 transaction for PureTech. PureTech obtained approval for the further disposals from more than 50% of its shareholders in advance of publication of the circular in accordance with a dispensation granted by the FCA pursuant to the temporary modifications made to the Listing Rules as set out in the FCA's Statement of Policy published on 8 April 2020.

Shortly following publication of PureTech's information only circular, the company announced the disposal of 1,333,333 shares in the common stock of Karuna pursuant to a block trade conducted by Goldman Sachs, raising proceeds of approximately US$100m.

The Ashurst team was led by corporate partner Simon Bullock, supported by senior associates Marianna Kennedy and Maria McAlister, and associate Oliver Perkins.

People

People Search

Locations

Services

Legal

Consulting

Industries

Industries

Innovation from Ashurst Advance

News & Insights

LATEST INSIGHTS

About Us

LATEST NEWS

Insights ()

People ()

Other Results ()

deals 28 Aug 2020 Ashurst advises Jefferies International as sponsor in relation to a Class 1 disposal by PureTech Health plc

Key Contacts

Keep up to date

My Documents

My Bookmarks

Get started

My Suggested Reading